olorofim
Orotomides are a class of experimental antifungals. They were discovered in 2015 by British scientists at the pharmaceutical company F2G Ltd. while searching for a new drug for Aspergillus infection. The discovery was formally announced at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 55th meeting during 17-21 September 2015 at San Diego, California, and published the next year in the Proceedings of the National Academy of Sciences. It was found to be effective against most important human fungal infections including those with Aspergillus, Lemontospora (Scedosporium) prolificans, Fusarium, Penicillium spp., and Taloromyces. The most promising drug candidate is designated F901318, chemical name 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide. F901318 has been named Olorofim. — Wikipedia
Clinical trial activity
20 trials · 12 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2014 (NCT02142153)
Timeline
Indications
Mechanism of action
- Aspergillus fumigatusINHIBITOR
Aspergillus fumigatus inhibitor
Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor
Chemistry & pharmacology
SMILES
Cc1cc(-c2ccccc2)c(C(=O)C(=O)Nc2ccc(N3CCN(c4ncc(F)cn4)CC3)cc2)n1C- Mol. weight
- 498.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOrotomide ↗
- ChEMBLCHEMBL4297609 ↗
Also known as
- f901318
- f901318
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05200286 | Phase 1 | Feb 10, 2022 | F2G Ltd. |
| NCT05101187 | Phase 3 | Nov 30, 2021 | F2G Ltd., IQVIA, Katholieke Universiteit Leuven |
| NCT04752540 | Phase 1 | Jun 17, 2021 | F2G Ltd. |
| NCT04207957 | Phase 1 | Dec 5, 2019 | Covance, F2G Ltd. |
| NCT04171739 | Phase 1 | Nov 18, 2019 | F2G Ltd., Hammersmith Medicines Research |
| NCT04039880 | Phase 1 | Jul 30, 2019 | F2G Ltd., Pharmaceutical Research Associates, Inc. (PRA) |
| NCT03583164 | Phase 2 | Jun 6, 2018 | F2G Ltd., IQVIA, University of Sydney |
| NCT03340597 | Phase 1 | Dec 12, 2017 | Covance, F2G Ltd. |
| NCT02912026 | Phase 1 | Jun 1, 2017 | F2G Ltd., Quotient |
| NCT03076905 | Phase 1 | May 1, 2017 | F2G Ltd., Quotient |
| NCT03095547 | Phase 1 | May 1, 2017 | Bio-Kinetic Clinical Applications, F2G Ltd. |
| NCT03036046 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2017 | F2G Ltd., University of Cologne |
| NCT02856178 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | F2G Ltd., University of Cologne |
| NCT02808741 | Phase 1 | Jul 1, 2016 | F2G Ltd., Quotient |
| NCT02737371 | Phase 1 | May 1, 2016 | F2G Ltd., Simbec-Orion |
| NCT02730442 | Phase 1 | Feb 1, 2016 | Celerion, F2G Ltd. |
| NCT02680808 | Phase 1 | Jan 1, 2016 | F2G Ltd., Hammersmith Medicines Research |
| NCT02394483 | Phase 1 | Oct 1, 2015 | F2G Ltd., Simbec-Orion |
| NCT02342574 | Phase 1 | Feb 1, 2015 | F2G Ltd., Hammersmith Medicines Research |
| NCT02142153 | Phase 1 | Aug 1, 2014 | F2G Ltd., Simbec-Orion |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| F2G Ltd. | For profit | 20 | 20 | 3 | 2014 |
| Hammersmith Medicines Research | For profit | 3 | 0 | 1 | 2015 |
| Quotient | For profit | 3 | 0 | 1 | 2016 |
| Simbec-Orion | For profit | 3 | 0 | 1 | 2014 |
| Covance | For profit | 2 | 0 | 1 | 2017 |
| IQVIA | For profit | 2 | 0 | 2 | 2018 |
| University of Cologne | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Bio-Kinetic Clinical Applications | For profit | 1 | 0 | 1 | 2017 |
| Celerion | For profit | 1 | 0 | 1 | 2016 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2019 |
| University of Sydney | Academic/Hospital | 1 | 0 | 1 | 2018 |